Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years

For an investor in their 50s or 60s who is finished chasing trends, Medtronic (NYSE:MDT | MDT Price Prediction) is a stock worth owning for decades because it pairs inelastic demand for medical devices with a 49th consecutive year of dividend increases. A $2,500 stake at the current $80.33 share price buys roughly 31 shares of a business engineered to keep paying you while the rest of the market cycles through manias.

Pillar 1: A Durable, Diversified Franchise

Medtronic is a diversified medical device juggernaut organized into four portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. That breadth matters because no single product cycle can sink the company. In fiscal 2026, revenue reached $36.36 billion, up 8.43% year over year, which CEO Geoff Martha called the “strongest annual top-line growth Medtronic has delivered in 10 years.” Cardiovascular alone produced $3.80 billion in Q4, with Cardiac Ablation Solutions growing 78% globally and capturing 8 additional points of U.S. market share. Pacemakers, spinal implants, insulin pumps and surgical navigation systems train surgeons on Medtronic’s proprietary ecosystems, creating switching costs that compound over decades alongside an aging global population that will keep filling cath labs and operating rooms.

Pillar 2: Income You Can Set and Forget

The forever case rests heavily on cash returned to shareholders. The board declared a $0.72 quarterly dividend on June 3, 2026, implying $2.88 annually and a yield of roughly 3.52%. That payout is funded by $5.43 billion in free cash flow and $7.33 billion in operating cash flow, with another $1.035 billion spent on buybacks in fiscal 2026. The quarterly dividend has climbed from roughly $0.04 in 1999 to $0.71 in early 2026, with the latest bump making it 49 straight years of increases. That is dividend aristocrat territory, and it is exactly the kind of compounding a retirement portfolio is built around.

Pillar 3: Built to Survive Market Cycles

Procedure volumes for cardiac ablation, pacemakers, spinal fusion and diabetes management are largely non-discretionary. People do not postpone life-saving devices because the S&P 500 is in a drawdown. That defensiveness shows up in a beta of 0.597 and in four consecutive quarterly EPS beats. Management guided fiscal 2027 to organic revenue growth of 6.75% to 7.25% and non-GAAP EPS of $5.90 to $6.00. Shares trade at a forward multiple of roughly 14x, an attractive entry for a business this defensive.

The One Scenario Where It Lags

In a low-rate, risk-on rally led by speculative growth names, Medtronic will trail. Margin pressure is also real: Q4 non-GAAP operating margin compressed 230 basis points to 25.5%, hit by the MiniMed Blackstone payment and a roughly $185 million tariff headwind. The 20-year case rests on demographics, switching costs and a dividend that has grown through every recession since the 1970s.

For long-term income investors, the thesis rests on reinvested dividends and a multi-decade holding horizon rather than short-term trading.